Cytosorbents Crp is a medical devices business based in the US. Cytosorbents Crp shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.92 – a decrease of 3.58% over the previous week. Cytosorbents Crp employs 186 staff and has a trailing 12-month revenue of around $37.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.92 |
|---|---|
| 52-week range | $0.70 - $2.15 |
| 50-day moving average | $1.13 |
| 200-day moving average | $0.99 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.36 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9595 from 2024-11-19
| 1 week (2024-11-14) | 1.01% |
|---|---|
| 1 month (2024-10-21) | -8.62% |
| 3 months (2024-08-21) | -9.48% |
| 6 months (2024-05-21) | 2.07% |
| 1 year (2023-11-21) | -26.19% |
|---|---|
| 2 years (2022-11-21) | -32.43% |
| 3 years (2021-11-19) | 5.24 |
| 5 years (2019-11-21) | 4.16 |
| Revenue TTM | $37.7 million |
|---|---|
| Gross profit TTM | $20.7 million |
| Return on assets TTM | -27.93% |
| Return on equity TTM | -118.5% |
| Profit margin | -49.47% |
| Book value | $0.24 |
| Market Capitalization | $51.9 million |
TTM: trailing 12 months
We're not expecting Cytosorbents Crp to pay a dividend over the next 12 months.
Cytosorbents Crp's shares were split on a 1:25 basis on 4 December 2014 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Crp shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Crp shares which in turn could have impacted Cytosorbents Crp's share price.
Over the last 12 months, Cytosorbents Crp's shares have ranged in value from as little as $0.7 up to $2.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Crp's is 0.564. This would suggest that Cytosorbents Crp's shares are less volatile than average (for this exchange).
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.